MAVS and myeloid leukemia: Nonetheless, PRMT9 has been identified as a potential target fortreating hepatocellular carcinoma,22,23 for suppressingacute myeloid leukemia maintenance,24 andit is required for androgen-dependent proliferation of LNCaP prostatecancer cells.25 It has been reported toplay a role in the regulation of alternative splicing.11,13 Very recently, it has been shown that PRMT9 attenuates activationof mitochondrial antiviral signaling protein (MAVS) through argininemethylation (R41 and R43), thus reducing innate antiviral immune response.26